Featured Research

from universities, journals, and other organizations

Study Shows Rapid Return To Menstruation Once Oral Contraception Stopped

Date:
May 8, 2006
Source:
Columbia University Medical Center
Summary:
A study by a Columbia University Medical Center researcher shows that 99 percent of participants experienced either a return to menstruation or became pregnant within 90 days after stopping an investigational, low-dose oral contraceptive taken every day without placebo. Findings from the first large clinical examination were presented this week at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical Meeting in Washington, DC.

A study by a Columbia University Medical Center researcher shows that 99 percent of participants experienced either a return to menstruation or became pregnant within 90 days after stopping an investigational, low-dose oral contraceptive taken every day without placebo. Findings from the first large clinical examination were presented this week at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical Meeting in Washington, D.C.

Anne R. Davis, M.D., assistant professor of clinical obstetrics and gynecology at Columbia University Medical Center, presented the findings abstract relating to a non-cyclic oral contraceptive, [90 ยตg levonorgestrel/20 ยตg ethinyl estradiol tablets], that would be taken every day of the year without a placebo interval. In contrast to a 28-day cyclic regimen, this regimen would be taken every day of the year, without a placebo (or sugar pill) interval, resulting in a temporary interruption of menses.

The follow-up study after a Phase 3, multicenter, open-label study of the safety and contraceptive efficacy of a non-cyclic oral contraceptive investigated return to menstruation after study participants stopped taking the contraceptive. Results showed that 185 of the 187 women in the study experienced either a return to menses or became pregnant within 90 days once they stopped the study drug after taking it for a median of 364 days. Four women became pregnant before returning to menses and two women reported a return to menses more than 90 days after the completion of the study.

"Patients want to know if, after taking an oral contraceptive every day without placebo pills, their menses will return," said Dr. Davis. "By evaluating this, we were able to learn that women who followed this daily regimen experienced a return to menses without a considerable delay."

The most widely used method of contraception in 1995 was oral contraceptives, used by 10.4 million women, according to National Survey of Family Growth (NSFG).


Story Source:

The above story is based on materials provided by Columbia University Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

Columbia University Medical Center. "Study Shows Rapid Return To Menstruation Once Oral Contraception Stopped." ScienceDaily. ScienceDaily, 8 May 2006. <www.sciencedaily.com/releases/2006/05/060508171336.htm>.
Columbia University Medical Center. (2006, May 8). Study Shows Rapid Return To Menstruation Once Oral Contraception Stopped. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2006/05/060508171336.htm
Columbia University Medical Center. "Study Shows Rapid Return To Menstruation Once Oral Contraception Stopped." ScienceDaily. www.sciencedaily.com/releases/2006/05/060508171336.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) — Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) — Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) — Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins